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Abstract 
The extracellular calcium-sensing receptor, CaSR, is expressed in blood vessels where its role 
is not completely understood. In this study, we tested the hypothesis that the CaSR expressed 
in vascular smooth muscle cells (VSMC) is directly involved in regulation of blood pressure 
and blood vessel tone. Mice with targeted CaSR gene ablation from vascular smooth muscle 
cells (VSMC) were generated by breeding exon 7 LoxP-CaSR mice with animals in which 
Cre recombinase is driven by a SM22α promoter (SM22α-Cre). Wire myography performed 
on Cre-negative (wild-type, WT) and Cre-positive 
SM22α
CaSR
∆flox/∆flox
 (knock-out, KO) mice 
showed and endothelium-independent reduction in aorta and mesenteric artery contractility of 
KO compared to WT mice in response to KCl and to phenylephrine. Increasing extracellular 
calcium ion (Ca
2+
) concentrations (1-5 mM) evoked contraction in WT, but only relaxation in 
KO aortae. Accordingly, diastolic and mean arterial blood pressures of KO animals were 
significantly reduced compared to WT, as measured by both tail cuff and radiotelemetry. This 
hypotension was mostly pronounced during the animals’ active phase and was not rescued by 
either NO-synthase inhibition with L-NAME or by a high salt-supplemented diet. KO animals 
also exhibited cardiac remodeling, bradycardia and reduced spontaneous activity in isolated 
hearts and cardiomyocyte-like cells. Our findings demonstrate a role for CaSR in the 
cardiovascular system and suggest that physiologically relevant changes in extracellular Ca
2+
 
concentrations could contribute to setting blood vessel tone levels and heart rate by directly 
acting on the cardiovascular CaSR.  
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Introduction 
The extracellular calcium-sensing receptor, CaSR, was the first G protein-coupled receptor 
identified that has an ion, Ca
2+
, as its primary physiological agonist. The CaSR was initially 
found in the parathyroid glands, where it acts as a controller of free ionized extracellular-Ca
2+ 
(Ca
2+
o) concentration in the blood via the regulation of parathyroid hormone (PTH) secretion 
(6). Systemic administration of pharmacological modulators of the CaSR have been shown to 
affect blood pressure in various animal models (50). However it is unknown whether these 
effects are due to systemic or local actions of the CaSR. Indeed, the CaSR expression is found 
in the vasculature (7, 54, 59), but a definitive role for this receptor in blood pressure 
regulation has never been firmly established. In the vascular endothelium, CaSR activation is 
thought to stimulate nitric oxide (NO) production (34, 59) and/or endothelium-derived 
hyperpolarization (EDH) (54). In rat subcutaneous small arteries, Ca
2+
o evokes a biphasic 
response with contraction followed by dilatation in a concentration-dependent manner (40). 
Furthermore, activation of the endothelial CaSR in mouse aortic segments induces 
endothelium-dependent and -independent relaxations (34). Alteration in CaSR expression or 
function in vascular smooth muscle cells (VSMC) has been linked to pathological conditions 
such as microvascular complications during diabetes (34), vascular calcification (1) and 
idiopathic pulmonary arterial hypertension (55). Allosteric CaSR activators, termed 
calcimimetics, have been on the market since 2004 for the treatment of hyperparathyroidism 
secondary to kidney failure (3). In patients with chronic kidney disease (60), and in a rat 
model of surgically-induced chronic kidney disease (39), calcimimetic treatment is associated 
with antihypertensive effects. However, because calcimimetics are phenylalkylamine 
derivatives, their ability to reduce blood pressure has been ascribed to potential off-target 
effects on L-type Ca
2+
 channels (37, 52). Given the importance of the CaSR in many 
physiological processes (43), the aim of this study was to determine whether the CaSR in 
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VSMC contributes directly to blood pressure regulation. For this purpose, we generated 
animals with targeted CaSR ablation from smooth muscle cells by breeding mice with LoxP 
sites flanking exon seven of the CaSR (13) with mice in which Cre recombinase expression is 
transcriptionally regulated by the SM22α promoter (30). This approach allowed us to study 
animals with targeted deletion of the CaSR from VSMC throughout the vascular system, 
visceral smooth muscle and cardiac cells, but not skeletal muscle cells (30, 56). 
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Materials and Methods 
Animals 
Commercially available SM22α-Cre+ mice (Jackson Immunoresearch Laboratories, Bar 
Harbor, ME, USA) were crossed with exon7-LoxP CaSR sites (13). The CaSR-LoxP strain 
was generated from C57BL/6 x SVJ129 backcrossed with C57BL/6 for 8 generations. CaSR-
LoxP x SM22α-Cre mice were inbred for at least 3 generations before being used for 
experiments. Genotyping for CaSR-LoxP sites and Cre was performed as described elsewhere 
(13, 25, 56). All animal work was conducted according to UK legislation (Home Office 
project license 30/3007) and conformed to the guidelines from directive 2010/63/EU of the 
European Parliament on the protection of animals used for scientific purposes. Euthanasia for 
tissue collection was performed by cervical dislocation according to UK legislation (A(SP)A 
1986, Schedule 1). 
 
Genotyping 
DNA from ear biopsies was extracted using DirectPCR® Ear DNA Extraction system 
(Viagen, Los Angeles, CA, USA) with proteinase K (Bioline, London, UK) according to the 
manufacturer’s instructions. Genotype was determined using the SM22α promoter and Cre 
coding region primers from (25) and the LoxP primers already described (13). Primer 
sequences: SM22-Pro (CAGACACCGAAGCTACTCTCCTTCC), SM22-Cre 
(CGCATAACCAGTGAAACAGCATTGC), CaSR fl up (GTGACGGAAAACATA CTGC), 
CaSR fl low (CGAGTACAGGCTTTGATGC). BioTaq Taq-polymerase (Bioline) was used 
for polymerase chain reaction (PCR). Final concentrations per reaction: 100 nM per primer, 1 
mM dNTPs (Bioline), 4 mM MgCl2, 2 U polymerase, 1.6 % ear lysate. PCR conditions: 5 
minutes initial denaturation at 95 °C, 40 cycles of 30 seconds 95 °C, 60 seconds 50 °C (Cre) 
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or 47 °C (LoxP), 120 seconds 72 °C, and a final elongation of 10 minutes at 4 °C. 
Amplification products for Cre were visualized using agarose gel electrophoresis with an 
expected amplicon size of 500 bp in case of at least one Cre-positive allele. Amplification 
products for LoxP were visualized using polyacrylamide gel-electrophoresis with an expected 
amplicon size of 167 bp for floxed alleles and 133 bp for non-floxed alleles. 
 
Chemicals and reagents 
All chemicals and reagents were obtained from Sigma-Aldrich (Poole, Dorset, UK) and Life 
Technologies (Paisley, Strathclyde, UK) unless otherwise stated. 
 
Real time reverse transcription PCR (RT-qPCR) 
RT-qPCR was performed on endothelium-denuded aortae as described previously (22). Gene 
expression was calculated based on the 2
-∆∆Ct
 method (33), normalized to the expression of the 
housekeeping gene β-actin. Samples with Ct values ≥ 31 for pecam-1 were considered to be 
devoid of endothelial contamination. Primers: Calcium-sensing receptor exon 6-7 (CaSR6-7) 
Fwd: GTGGTGAGACAGATGCGAGT; Rev: GCCAGGAACTCAATCTCCTT. β-actin 
(Fwd: TCCTAGCACCATGAAGATCA; Rev: CCACCGATCCACACAGAGTA), Pecam-1 
(Fwd: AGACATGGAATACCAGTGCAGAG; Rev: 
ACAGGATGGAAATCACAACTTCAT). 
 
Western Blot 
CaSR immunoblot of microsomal membrane fractions from endothelium-denuded aortae or 
lysate from HEK-293 cells stably expressing the human CaSR (positive control) was 
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performed as described previously (53) using an antibody directed against the amino terminus 
of the CaSR (Anaspec, Freemont, CA, USA). Expression of α-smooth muscle actin was 
detected using a mouse monoclonal antibody.  
 
Intracellular calcium imaging 
The thoracic aorta was dissected and cleaned in cold DMEM-F12 supplemented with 1% 
penicillin/streptomycin (Life Technologies, Paisley, U.K.), cut-open for endothelium removal 
and cut into 1-2mm segments, subsequently incubated for 30 minutes at 37 ºC in 5% CO2 in 
an enzymatic digestion solution containing DMEM-F12 supplemented with 1 mg/ml papain, 
1mg/ml collagenase from Clostridium histolyticum, 1 mg/ml fatty acid free BSA, 1 mg/ml 
DTT and 0.5 mg/ml soybean trypsin inhibitor. The cell suspension was seeded onto glass 
coverslips coated with poly-D-lysine and allowed to settle for 30 minutes at 37 ºC in 5% CO2, 
after which cells were incubated for 30 minutes with extracellular solution (135 mM NaCl, 10 
mM glucose, 5 mM KCl, 5 mM HEPES, 1.2 mM MgCl2, 1 mM CaCl2, pH 7.4) containing 1.4 
µM fura-2 AM, dissolved in DMSO (Life Technologies). Ca2+i recordings were performed as 
described previously (46). 
 
Wire myography  
Wire myography on mouse aortae and MA was performed as described elsewhere (5, 17, 19). 
In brief, thoracic aortae and second order MA of 4-6 month old mice were carefully dissected 
in cold buffer (118 mmol/l NaCl, 3.4 mmol/l KCl, 1.2 mmol/l KH2PO4, 1.2 mmol/l MgSO4, 
25 mmol/l NaHCO3, 11 mmol/l glucose, 1 mmol/l CaCl2, bubbled with 95% O2/5% CO2) and 
cut into 2 mm segments. For the study of vascular responses to the calcimimetic NPS-R-568, 
the extracellular solution contained 1.5 mM CaCl2. The vessel rings were then carefully 
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mounted in a wire myograph (Danish MyoTechnology, Aarhus, Denmark) using two gold-
plated tungsten wires (d = 25 μm) for MAs, or stainless steel wires (d = 40 μm) for aortas. 
The vessels were let to equilibrate for 20 min at 37
o
C, and then gradually stretched (up to 2 
mN for mesenteric arteries and 5 mM for aorta). The plateau values after each stretch were 
used to calculate the lumen diameter that would give a target transmural pressure, which for 
MAs was set as 70 mmHg, and for aortas - 100 mmHg. After normalization, vessels were left 
to equilibrate for another 30 min, and tested for viability using phenylephrine (PE) and 
acetylcholine (ACh). Where stated, the endothelium was removed by gentle rubbing of the 
vessel lumen with a clean human hair, or an air bubble was pushed through the lumen of the 
vessel. Lack of relaxation in response to 10 µM ACh was used to confirm the successful 
endothelial denudation. High KCl (40 mM) was used as an alternative, depolarizing, 
vasoconstrictor (11, 41, 51). When required, the vessels were pre-treated with Nitro-L-
arginine methyl ester (L-NAME) for at least 20 min prior to the experiment, and 
concentration-response curves were obtained by cumulative addition of rising concentrations 
of the agonists (PE, ACh, CaCl2 and SNAP) directly to the bath. Solutions were changed 
every 20 minutes to avoid alterations of osmolarity. In order to calculate the percentage 
change in contractility of KO vessels in comparison to WT, each contraction data point was 
normalized to the average of individual maximal contraction values of WT vessels. For the 
dilatation experiments, vessels were first pre-contracted with PE, and then vasodilators were 
added to the bath. 0% relaxation is the level of tension before the vasorelaxant agonist was 
added, and 100% relaxation reflects the return of the tension to the basal level.  
 
Tail cuff and radiotelemetry measurements 
Blood pressure of male, age-matched animals (4-9 months) were measured by tail cuff on 
awake, conscious animals during day-time using a 2-channel CODA system (Kent Scientific, 
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Torrington, CT, USA), following the manufacturer’s instructions and using 20 acclimatization 
and 10 measurement cycles. 
Radiotelemetry was performed on 3 month old mice using implantable probes with HD-X11 
transmitters (4). Mice were anesthetized by subcutaneous injections with a combination of 
fluanisone (10 mg/kg body weight), fentanyl (0.3 mg/kg body weight) and midazolam (1 
mg/kg body weight) and placed in dorsal recumbence on a thermostatically controlled heating 
platform for maintaining body temperature at 37.5°C. The body hair was liberally removed 
from the skin on the neck and the skin was disinfected by isopropyl alcohol. A 1‒1.5 cm long 
midline incision through the skin on the neck was made and the mandibular glands were 
carefully separated. The carotid artery along the left side of the trachea was carefully isolated 
with fine‒tipped forceps from the surrounding tissues. The distal side of the carotid artery 
(just before the bifurcation) was occluded permanently with 6-0 non-absorbable suture and 
another suture was placed proximately for temporal occlusion of blood flow to allow for 
placement of the catheter. Additional suture was placed in the middle to hold the catheter in 
place after the cannulation of the artery. The artery was pierced using the 25-gauge bent 
needle just proximately the permanent ligation suture and the catheter was inserted into the 
vessel using Vessel Cannulation Forceps (Data Sciences International, USA). The catheter 
was advanced into the artery until it reaches the occlusion suture, the loose middle suture was 
tightened and occlusion suture released. The catheter was then advanced further until the 
sensing region was positioned in the aortic arch. The occlusion suture was tightened and a 
subcutaneous pocket was made by inserting small surgical scissors. A HD-X11 radiotelemetry 
transmitter (Data Sciences International, USA) was then placed in the pocket. The terminal 
end of the positive lead was positioned with a small hemostat subcutaneously from the neck 
incision to the left caudal rib region (approximately 1 cm to the left of the xyphoid process). 
The negative lead terminal end was positioned with a small hemostat subcutaneously from the 
neck incision to the right pectoral muscle. The skin incision was closed using 6-0 non-
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absorbable suture. Painkiller (0.2 ml/kg; Temgesic, Schering-Plough Europe, Belgium) was 
injected subcutaneously at the end of operation. Mice were allowed to recover for 2 days 
before housing them in metabolic cages where they were kept on control diet for 4 days. The 
standard (control) diet was then changed to a high salt diet (containing 4% NaCl) for a period 
of 5 days. For reasons of animal welfare, mice were then transferred back in normal housing 
cages and kept on standard diet for a washout period of 3 days, after which drinking water of 
the mice was supplemented with 0.5 g / L L-nitro-arginine-methyl-ester (L-NAME).  
Telemetry signals from the probes were recorded for the whole duration of the experiment in 
intervals of 5 minutes in quintuplicates resulting in 60 measurements per hour. Registration 
was performed with Dataquest A.R.T™ software 4.3. Analyses were performed with 
Ponemah analyses software 5.00 (all Data Sciences International, USA) and Microsoft Excel 
2010. Raw values were concentrated to hourly datapoints. For statistical analysis, three hour 
intervals of the raw data were averaged for night-time (active phase, 20:00-23:00) and day-
time (resting phase, 8:00-11:00). The standard diet vs. high salt diet and standard diet vs. 0.5 g 
/ L L-NAME diet phases were treated as two separate experiments because of the different 
housing conditions. For graphical representation only, traces were calculated as rolling 
average over 4 hours. 
 
Cardiac cine-MRI 
Cardiac cine-MRI (magnetic resonance imaging) scans of aged (14 month old) mice were 
acquired using a Bruker Biospec 94/20 9.4 Tesla small bore (20 cm) MRI spectrometer 
equipped with S116 high performance gradient insert and Avance II electronics (Bruker, 
Ettlingen Germany). Scans were acquired using a 72 mm transmit/receive quadrature 
polarized birdcage coil. Mice were kept under general anesthesia using 1-5 % isoflurane in a 
40% O2 / air at 1.2 L / min during scanning. Animals were ECG, respiration and temperature 
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monitored using a Model 1025 monitoring and gating system (SAIInc, Stony Brook, New 
York, USA). The temperature of the animals was kept at 37 °C using temperature controlled 
bath feeding into the restraining scaffold. T2 weighted, respiratory and cardiac gated, fast-
imaging with steady-state precession pro-cine scans were performed with a field of view of 32 
× 32 mm, an echo time of 1.228 ms, a repetition time of 5 ms, a band width of 125 kHz and 
slice thickness of 1-1.5 mm were collected from apex to the aortic arch using Paravision 5.0 
(Bruker). Gating was performed using using the Small Animal Monitor software and 
monitoring equipment according to the manufacturer’s instructions (SA Instruments, Stony 
Brook, NY, USA). Scans performed for each mouse included Tri-axial pilot orientation scan, 
central long-axis cine-scan, short axis cine-scans coving sub-apical to supra-basal image 
plane. Scans were analyzed using the academic version of Segment 1.9 R2626 
(http://segment.heiberg.se) (21) by one person blinded to the genotype of the animals. 
Functional parameters were assessed from multi-slice short-axes cine MR images by manual 
markup of left-ventricular endocardium and epicardium in the first timeframe of the slice 
showing the papillary muscles. The markup was then propagated in time and adjusted to fit 
the new timeframe. After the markup of the slice was completed, the markup for the whole 
cine-cycle was propagated apically and basally and contours were again adjusted to fit the 
respective scans. End-diastole and -systole were defined as the timeframe showing highest 
and lowest ventricular volume using the auto-detection feature of the Segment software. For 
wall thickness measurements, the thicknesses of the second and third apical slice in end-
systole and -diastole, measured with the respective tool in the Segment software, were 
averaged. Based on the long axis scans, hearts of KO animals showing full apical end-systolic 
closure were selected as remodeled sub-group.  
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Histomorphology and fibrosis staining 
Sections from paraffin-embedded hearts and aortae were stained with haematoxylin and eosin 
(H&E). To detect fibrosis in heart sections of aged mice, collagen deposition was visualized 
in 8 µm cryosections of paraformaldehyde-fixed hearts stained with picrosirius-red mixture. 8 
µm cryosections of paraformaldehyde-fixed (4% in phosphate buffer saline (PBS) for 4 hours) 
hearts of adult mice were thawed in PBS-T (0.1% Tween-20) for 20 minutes and washed in 
distilled water for 2 minutes. Sections were then pre-stained with 0.1% fast green for 15 
minutes, washed twice in 1 % acetic acid for 15 seconds, washed in distilled water for 2 
minutes. Final staining was achieved by incubation in a solution of 0.1 % fast green, 0.1% 
direct red and 1.3 % picric acid for 1 hour. Sections were then washed three times in 1 % 
acetic acid for 15 seconds and distilled water for 2 minutes and finally dehydrated in rising 
concentrations of ethanol, cleared in xylene and mounted in DPX:Xylene 4:1, resulting in 
green staining for all tissues and red staining for fibrotic tissue. Fibrotic area was quantified 
using CellProfiler 2.1.1 (28) by one person blinded to the genotype of the animals. All 
epicardial and endocardial positive (red) staining was manually removed along with other 
image artefacts (e.g. tissue folding). An image analysis pipeline was run to separate different 
shades of red pixels (fibrosis positive) from background tissue (green). Cardiac fibrosis 
percentage was calculated by dividing the number of detected red pixels per 100 positively 
stained pixels (red + green). 
 
Ex vivo measurement of baseline heart rate 
Rapidly dissected hearts were retrogradely perfused in Langendorff fashion. Baseline heart 
rates were measured using longitudinal force tonometry (31). 6 month old male mice were 
killed by cervical dislocation. The thorax was rapidly opened and the heart, lungs and thoracic 
aorta removed to ice cold Krebs buffer (118 mmol / L NaCl, 3.4 mmol / L KCl, 1.2 mmol / L 
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KH2PO4, 1.2 mmol / L MgSO4, 25 mmol / L NaHCO3, 11 mmol / L glucose, 1 mmol / L 
CaCl2). The aorta was cannulated with a gauge 20 hypodermic needle filled with Krebs buffer 
and the tip of the needle was advanced to the aortic valve. The needle was attached to the 
perfusion apparatus and the heart perfused in Langendorff mode (31) at a constant flow rate of 
3 ml/min (Gilson Minipuls 3 peristaltic pump, Gilson, Luton, UK) with warmed (37.5°C) 
Krebs buffer pregassed with O2/CO2 (95%/5%). Coronary perfusion pressure was measured 
by means of a pressure transducer (MLT 844, ADInstruments, Chalgrove, UK) located 
immediately before the warming coil, where a Condon mercury manometer was also located 
to accommodate perfusion fluid during pressure changes. A clip was attached to the apex of 
the heart and linked via a thread and pulley to an isometric tension transducer (50g sensitivity 
range) (ADInstruments) for measuring contractile tension. A resting diastolic tension of 2g 
was applied at the start of the experiment and readjusted periodically. The heart was 
surrounded by a heated jacket (37.5
 
°C). Isometric cardiac contractions were recorded by 
means of a Powerlab 8/30, Chart 5, data acquisition system (ADInstruments) and heart rate 
was derived from the cardiac contractions signals. 
 
Spontaneous activity of PVC in lung slices 
Murine lung slices were prepared as described previously (44). In brief, 4-6 month old mice 
were killed by cervical dislocation and, after opening of the chest cavity, the trachea was 
cannulated and lungs were inflated by injecting ~ 1.2 ml of low melting point agarose (37 °C, 
1.8 % in sHBSS; Life Technologies, Paisley UK). The agarose was stiffened by applying cold 
sHBSS supplemented with 20 mM HEPES, pH 7.3) over the lungs. The stiffened lungs were 
cut into ~ 180 µm thick slices using a Vf-300 microtome (Precisionary Instruments, 
Greenville, NC, USA). Slices were kept in a humidified cell culture incubator with 5 % CO2 
in DMEM:F12 (Life Technologies), supplemented with 10 % FBS. Slices were loaded in the 
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dark with 20 µM Oregon-Green BAPTA-1 AM (Life Technologies) in the presence of 0.1 % 
Pluronic F127 (Life Technologies) and 200 µM sulfobromophtalein in sHBSS at room 
temperature for one hour, followed by de-esterification for at least 30 minutes in the dark in 
sHBSS with 200 µM sulfobromophtalein. Slices were then mounted in a custom-built 
imaging chamber and imaged on a Nikon Eclipse Ti microscope, using a Nikon S Fluor 40x 
oil immersion objective, with an excitation of 470 ± 15 nm. Emission was measured at 525± 
25 nm. Images were acquired with a frame rate of 25 frames per second using OptoFluor 
software (Cairn Research, Faversham, U.K.). Image acquisition was performed for ~ 20 s 
periods to record the frequency of the spontaneous activity. Image analysis was performed 
using ImageJ software (47). 
 
Statistical analyses 
Statistical analyses were performed using GraphPad Prism 6.04 (GraphPad Software, La 
Jolla, CA, USA). Statistical tests employed are stated with the respective results or in the 
figure legends. Where two curves were compared, asterisks (*) above individual data points 
indicate point-by-point comparison by Holm-Sidak post-test of two-way ANOVA; plus-signs 
(+) indicate difference of the fitted curves by extra sum-of-squares F test and two-way 
ANOVA. N states the number of individual biological repeats (number of animals, cell 
batches, etc.). 
 
Results  
Generation of 
SM22α
CaSR
∆flox/∆flox
 mice  
Breeding of SM22α-Cre+ mice with mice in which LoxP sites flanked exon 7 of the CaSR 
gene (LoxP-CaSR
+/+
) (13) yielded 
SM22α
CaSR
∆flox/∆flox
 mice (which were termed “knockout”, 
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“KO”). Age- and sex-matched mice expressing only floxed CaSR alleles but no Cre-
recombinase (SM22α-Cre-/--LoxP-CaSR+/+) were used as controls for all experiments (termed 
wild-type, “WT”). The resulting truncated Δexon7 product was shown to be non-functional 
(13) and these animals are viable and fertile (56). Representative genotyping is shown in 
Figure 1A. Aortae of KO animals appeared histomorphologically normal and 
indistinguishable from those of WT mice of comparable ages (Figure 1B), suggesting that 
CaSR deletion does not affect the histomorphology of blood vessels.  
Molecular and functional CaSR expression in the vasculature was found to be significantly 
reduced in KO compared to WT animals. Bona fide, CaSR-like immunoreactivity, 
corresponding to the molecular mass of the fully mature dimeric form of the receptor, (53) 
was reduced in membrane fractions from endothelium-denuded KO aortae compared to that 
seen in WT, as shown by western blot using a polyclonal antibody that preferentially detects 
the dimeric form of the CaSR. CaSR deletion from VSMC did not affect the expression levels 
of α-smooth muscle actin (Figure 1C). RT-qPCR carried out in endothelium- and adventitia 
denuded aortae from WT and KO animals showed that expression of the CaSR (exon 6-7) was 
significantly reduced in KO vessels compared to WT (Figure 1D). Classically, CaSR 
activation is linked to phosphoinositide turnover and an increase in intracellular Ca
2+
 
concentration ([Ca
2+
]i) (6). In fura-2 loaded VSMC isolated from WT and KO mouse aortae, 
increasing [Ca
2+
]o from 0.1 to 5 mmol / L evoked a concentration-dependent increase in 
[Ca
2+
]i in WT VSMC, which was significantly smaller in KO VSMC (Figure 1E). 
 
Ex vivo blood vessel contractility is impaired in
 SM22α
CaSR
∆flox/∆flox
 mice  
Previous studies have suggested a role for the CaSR in vascular tone regulation (50). To test 
this hypothesis directly, we performed ex vivo tension measurements on isolated aortae and 
mesenteric arteries (MA) from WT and KO mice. Rings of aortae and MA of KO animals 
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showed a significantly smaller contraction in response to a depolarizing stimulus (i.e. high 
K
+
) compared to aortic rings from WT (Figure 2A and 2B). A comparable level of reduction 
in KO aortae and MA contractility was observed when phenylephrine (PE, 1 nmol / L – 30 
µmol / L), an agonist of the Gq/11 protein-coupled α1-adrenoceptor, was employed (Figure 2C 
and 2D). Except for the responses to PE, where potency was slightly but significantly reduced 
in KO aortae and MA compared to WT control, EC50 values in all other experiments remained 
unchanged (Table 1). In contrast, endothelium-dependent relaxation of PE-precontracted 
blood vessels in response to acetylcholine (ACh) was modestly, but significantly enhanced in 
KO aortae (Figure 2E), and reduced in KO MA (Figure 2F). 
In line with this reduction in contractility in response to contractile stimuli, we observed a 
reduction in Ca
2+
i signaling in VSMC isolated from KO mice compared to WT cells in the 
presence of depolarizing concentrations of K
+
 (60 mmol / L KCl, KO vs WT: 3.81 ± 0.62 vs. 
1.90 ± 0.53 fold vs. baseline, N = 5, p < 0.05, Student’s t-test).  
To investigate the effects of the physiological CaSR agonist, Ca
2+
o, on the vascular tone, we 
precontracted aortae and MA from WT and KO animals with PE to approximately 60% of 
maximal tone, and then cumulatively added rising concentrations of Ca
2+
o (from 1 to 5 mmol / 
L). Aortae of WT animals displayed significantly different response to Ca
2+
o than aortae from 
KO animals, showing a moderate contraction to Ca
2+
o that reached 19.9 ± 7.8 % at 2.5 mmol / 
L Ca
2+
o: (p < 0.05, one sample t test vs baseline), whilst aortae from KO animals showed only 
relaxation that reached 33.4 ± 11.8 % in the presence of 4 mmol / L Ca2+o (p < 0.05, one 
sample t test vs baseline; Figure 2G). In contrast, MA displayed only relaxation to rising 
[Ca
2+
]o
 
that was of comparable magnitude in vessels from WT and KO animals (Figure 2H). 
In order to determine CaSR specificity of the responses observed in the aortae, aortic rings 
were preconstricted with PE to ~ 60% of maximal tone, and then treated with increasing 
concentrations of the calcimimetic NPS R-568 (10 nM-10 µM). NPS R-568 evoked 
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contraction followed by relaxation in WT aortae while KO aortae were insensitive to low 
concentrations of calcimimetic (10 nM – 300 nM) and only responded with vasodilation at 
concentrations higher than 1 µM NPS R-568 (Figure 3A). After removal of the endothelium, 
aortae from WT mice still showed a contractile response to rising concentrations of NPS R-
568 but did not show any relaxation even at very high levels of the calcimimetic. Endothelium 
denuded aortae from KO animals were completely insensitive to NPS R-568 (Figure 3B).  
Inhibition of nitric oxide synthase (NOS) with NG-nitro-L-arginine methyl ester (L-NAME) 
(100 µmol / L) (Figure 4A and B) or endothelial denudation (Figure 4C and D) did not 
abolish the reduction in contractility in KO aortae and MA compared to WT. These results 
indicate that the impaired vascular contractility observed in KO animals was not due to an 
increase in endothelium-mediated relaxation. Abrogation of NO signaling with L-NAME led 
to ACh-induced contraction (16, 27, 42) in both WT and KO aortae which again was 
significantly smaller in aortae from KO animals compared to WT (Figure 4E, negative 
relaxation = contraction). In MA, L-NAME abrogated the differences in the relaxation 
response to ACh between KO and WT (Figure 4F). Endothelium-independent relaxation 
following treatment with the NO donor S-Nitroso-N-acetylpenicillamine (SNAP; 1 nmol / L – 
30 µmol / L) showed no difference in ACh sensitivity between WT and KO endothelium-
denuded aortae and MA (Figure 4G and H). EC50 values of all agonists in these series of 
experiments were unchanged between WT and KO animals (Table 1). 
 
SM22α
CaSR
∆flox/∆flox
 mice are hypotensive 
The impaired vascular contractility of KO mice suggested an effect of VSMC-CaSR deletion 
on blood pressure in vivo; and indeed, tail cuff measurements in adult male mice showed that 
KO animals exhibited a reduction in blood pressure (approximately 5% systolic, 9% diastolic 
and 7% mean arterial pressure, MAP) compared to the WT (Figure 5A-C). Longitudinal 
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radiotelemetry experiments confirmed this reduction in systolic and diastolic blood pressure 
and MAP. Notably, this reduction was only apparent during night-time, when the animals 
were active, but not during day-time when the animals were resting. Short-term L-NAME 
treatment (38) increased blood pressure in animals of both genotypes but did not abolish the 
hypotension of KO relative to WT mice (Figure 5D-F and Table 2). Pulse height was 
increased in KO animals compared to WT mice (Figure 5G), particularly following L-NAME 
treatment, owing to the bigger difference in diastolic than systolic pressures between the 
genotypes. Short-term dietary NaCl supplementation yielded no changes in systolic or 
diastolic blood pressure in either WT or KO animals (Table 2).  
 
SM22α
CaSR
∆flox/∆flox
 mice are bradycardic 
In addition to the impaired vascular reactivity that is associated with hypotension in the 
SM22α
CaSR
∆flox/∆flox
 mice, radiotelemetry experiments also revealed that heart rates of these 
animals were about 5 % (day-time) to 17% (night-time) below those of WT mice (Figure 6A 
and Table 2). Furthermore, during night-time, the positive first derivative of the blood 
pressure curve (dp/dt), an indirect measure of inotropy (36), was significantly higher in the 
KO compared to WT mice. Short-term L-NAME treatment, while decreasing heart rate in 
mice of both genotypes, did not affect the difference in heart rates between WT and KO 
animals nor did it influence dp/dt in these animals (Figure 6B and Table 2). A high salt diet 
led to a small reduction in heart rate of WT and KO animals during day-time and did not 
affect dp/dt (Table 2).  
 
SM22α
CaSR
∆flox/∆flox
 mice exhibit cardiac remodeling 
The observed bradycardia presented by the KO mice could be accounted for, at least in part, 
by direct CaSR ablation from cardiomyocytes as the SM22α promotor has been shown to 
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direct Cre expression transiently to the heart (30). This consideration, together with recent 
evidence suggesting that the CaSR plays a role in electromechanical coupling of 
cardiomyocytes (48), led us to investigate more thoroughly the cardiac phenotype of 
SM22α
CaSR
∆flox/∆flox
 mice. While there were no differences between hearts from WT and KO 
animals by superficial observation or any histomorphological changes seen by H&E staining 
(Figure 7A), KO animals showed a reduction in fibrosis when compared to age-matched WT 
controls (Figure 7B) (0.93 ± 0.08 vs. 2.09 ± 0.43 % fibrotic area, N = 9 (KO), 10 (WT), p < 
0.05, Student’s t-test with Welch’s correction). 
Cardiac cine-MRI showed that the long axes of WT and KO hearts of aged animals were 
comparable between genotypes in end-diastole but presented with a visible difference in end-
systole in hearts from 5 out of 11 investigated KO animals. In these hearts, complete closure 
of the apical left ventricular cavity (2
nd
 apical short-axis MRI slice) was seen, while it was 
still visible at the end-systole of the hearts of WT mice (Figure 7C, Video S1). These 
functional differences can be easily observed in morphological 3D reconstructions of the left 
ventricle endocardium (Figure 7D). These 5 hearts were thus termed “remodeled” and 
analyzed as a separate group. MRI analysis showed that left ventricular mass (Figure 7E), left 
ventricular end-diastolic volume (Figure 7F) and end end-diastolic volume (Figure 7G) and 
stroke volume (Figure 7H) were unaltered between WT and remodeled KO hearts. An 
observed decrease in end-systolic volume did not reach statistical significance. Ejection 
fraction (Figure 7I), end-diastolic remodeling index (Figure 7J, size of the ventricle vs. the 
end-diastolic volume) and wall thickening (Figure 7K) were increased in remodeled hearts 
from KO mice compared to WT hearts.  
To test more directly the hypothesis that direct CaSR ablation from cardiomyocytes was 
responsible for the observed bradycardia in the 
SM22α
CaSR
∆flox/∆flox
 mouse, we also 
investigated the base frequency of non-paced hearts from WT and KO mice ex vivo in the 
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absence of autonomic regulation in a retrogradely perfused Langendorff preparation (31). 
Isolated hearts from KO animals showed a significantly reduced basal heart rate compared to 
that measured in the hearts of WT animals (Figure 7L), suggesting that CaSR deletion from 
the heart has a direct impact on chronotropy. Pacemaker activity also occurs in the pulmonary 
veins, which contain cardiomyocyte-like pulmonary vein sleeve cells (PVCs). PVCs employ 
the same electrochemical coupling machinery as atrial cardiomyocytes (14), can act as 
pacemaker cells (12, 26, 57) and can be easily studied in ex vivo lung slice preparations as 
they are present in the murine lung. In PVCs from KO animals, there was a reduced rate of 
spontaneous activity, measured as changes in Ca
2+
i compared to WT mice (KO vs WT: 0.58 ± 
0.10 vs 1.00 ± 0.09 fold, N = 6, p < 0.05, Student’s t-test), suggesting that the bradycardia is 
an intrinsic feature of the KO animals. 
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Discussion 
Vascular phenotype 
SM22α
CaSR
∆flox/∆flox
 mice show changes in their cardiovascular system: the main findings of 
this study are that 
SM22α
CaSR
∆flox/∆flox
 mice exhibit impaired vasoconstriction, systemic 
hypotension and bradycardia. 
Ex vivo tension measurements of aortae and mesenteric arteries from WT and KO mice 
demonstrated impaired contractile responses to high K
+
, (a depolarising stimulus) and 
impaired maximum contractility in response to PE (GPCR-mediated). In addition, the potency 
of PE to contract KO blood vessels was also impaired. These findings indicate that the CaSR 
sensitizes the response of blood vessels to contractile stimuli. Importantly, no histological 
difference was found between blood vessels from WT and KO mice, indicating that changes 
in vessel morphology were not responsible for the observed changes in blood vessel 
contractility. Furthermore, the reduction in maximum contractility was independent of 
inhibition of NOS or endothelial denudation while vascular relaxation in response to an 
exogenous NO donor remained unchanged. In addition, inhibition of NOS signaling can 
unmask the effects of endothelium-derived contracting factors released from the endothelium 
upon stimulation that in the absence of NO can cause pronounced vasoconstriction  (16, 27, 
42). This contractile effect of ACh in the presence of L-NAME was reduced in KO compared 
to WT aortae, providing yet another indication that the impaired contractility of blood vessels 
lacking the VSMC CaSR is independent of the contractile stimulus. 
Despite the fact that the sensitivity to an NO donor was comparable in WT and KO vessels, 
the endothelium-dependent relaxation was differentially affected in MA and aortae. ACh 
evoked enhanced relaxation in KO aortae which may be explained by the aforementioned 
reduced contractile component of the ACh response. KO MAs, in contrast, exhibited a small 
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but significant suppression of the ACh-mediated relaxation that was absent when L-NAME 
was added. These findings suggest a reduced endothelium-derived NO signalling in MA, as 
induced by endothelial stimulation (e.g. ACh), while the sensitivity of VSMC to NO itself 
was unaffected in KO animals.  
In line with our results of genetic ablation, Loot and colleagues have recently found that 
pharmacological inhibition of the CaSR attenuated vascular contraction in response to PE and 
high K
+
 (34). The congruence of these results of pharmacological CaSR inhibition in wild 
type mice and CaSR ablation in genetically altered mice provides another line of evidence 
that the VSMC-CaSR is indeed directly responsible for the modulation of vascular tone, 
rather than possible off-target effects of calcilytic drugs (35) or unexpected side-effects of the 
genetic ablation. This contractility-enhancing effect of the CaSR is not limited to VSMC, 
since, using the same animal model as the one we have used for the current studies, we have 
recently reported that airways of KO mice showed a reduction in contractility in response to 
the muscarinic ACh receptor agonist methacholine when compared to WT mice (56), 
similarly to the observed reduction in blood vessel contractility in response to PE in this 
study. Finally, the observed effects in
 SM22α
CaSR
∆flox/∆flox
 mice were unlikely to be due to 
impaired SM22α function, as constitutive ablation of SM22α was shown to lead to increased 
MA vasoconstriction in response to an α1-adrenoceptor agonist (58). In the current study, the 
CaSR agonist, Ca
2+
o, induced vasorelaxation in WT and KO MA and KO aortae, likely due to 
stimulation of the endothelial CaSR (34, 54, 59). However, in WT aortae, we observed Ca
2+
o 
concentration-dependent vasoconstriction. These effects of increasing Ca
2+
o concentrations 
inducing vasoconstriction in WT aortae are consistent with previous findings by Ohanian and 
colleagues (40), who reported vasoconstriction in response to physiological Ca
2+
o 
concentrations in rat subcutaneous small arteries. These authors suggested that the contractile 
effect was not CaSR-mediated. Similary, Loot and colleagues have reported vascular 
contraction in response to rising concentrations of Ca
2+
o in endothelium denuded or L-NAME 
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treated mouse aortic rings (34) Here, we have demonstrated that the contracting component of 
th.e Ca
2+
o response was lost in KO aortae. Similarly, airways of WT mice have been shown to 
react with robust contraction to rising concentrations of the CaSR agonists, Ca
2+
o and 
spermine, and this contractile response was completely lost in airways from animals lacking 
the CaSR in smooth muscle cells (56). Moreover, results obtained by treating PE-
preconstricted aortae with the calcimimetic NPS-R-568 mimicked the results observed by 
using Ca
2+
o to modulate vascular tone. The calcimimetic-mediated contraction in WT aortae 
was endothelium independent, further corroborating a role for the VSMC CaSR in vessel 
contractility. Together, these results clearly support the idea that the CaSR mediates Ca
2+
o-
induced contractions in smooth muscle cells. Cultured VSMC of KO animals reacted with 
impaired Ca
2+
i mobilization to stimulation with both Ca
2+
o and K
+
, indicating Ca
2+
i-signalling 
as one mechanism of action by which the CaSR affects blood vessel tone. Together, these 
results demonstrate that the observed impaired vascular contractility in blood vessels of 
SM22α
CaSR
∆flox/∆flox
 mice, as shown by reduced responses to primary contractile stimuli, is an 
effect, which is independent of the endothelium and dependent on VSMC CaSR.  
Tail cuff and radiotelemetry measurements confirmed the hypotensive phenotype of 
SM22α
CaSR
∆flox/∆flox
 animals which was predicted from the ex vivo vessel tone studies. In both 
circumstances, we observed a significant reduction in diastolic blood pressure and MAP. This 
reduction was more apparent during the animals’ active than resting phase, suggesting that the 
modulating effect of the CaSR on blood pressure is dependent on sympathetic activity, again 
supporting the idea that the effects of the CaSR on blood vessel tone and blood pressure are 
dependent on the presence of other contractile, or activating, stimuli. A contribution of the 
cardiac phenotype of the animals, i.e. the reduction in heart rate, to the observed hypotension 
in 
SM22α
CaSR
∆flox/∆flox
 animals is likely, although the stronger reduction in diastolic than 
systolic blood pressure points to peripheral resistance being the principal cause of the 
hypotension in KO animals. 
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Acute L-NAME treatment did not abolish this difference in WT and KO mice’ diastolic blood 
pressure, mirroring the aforementioned ex vivo results on isolated blood vessels, where NOS-
inhibition or endothelial denudation did not abolish the impaired vascular contractility either. 
This rules out the possibility that, at least in the short-term, the difference in blood pressure 
between WT and KO mice might be NO-driven. Short-term exposure to a high salt-
supplemented diet has been shown to rescue the loss of angiotensin converting enzyme-
induced hypotension in mice of a similar background (9). However, the lack of any change in 
blood pressure in KO animals kept on a high salt diet here suggests that the kidney is not 
likely to be involved in causing the observed hypotension in our strain. 
Pulse height was increased in KO animals following L-NAME treatment. While elevated 
pulse height is recognized as being a feature of increased arterial stiffening, reduced blood 
vessel compliance is also accompanied by isolated systolic hypertension in humans and 
animals (15, 18), which clearly is not the case in KO animals. Indeed, the increased pulse 
height can be attributed solely to the greater reduction in diastolic than systolic blood pressure 
in KO animals. In KO animals, L-NAME treatment induced a larger increase in systolic blood 
pressure (and, therefore, pulse height) than diastolic blood pressure. It is known that the 
importance of endothelium-dependent NO signaling declines with the reduction of arterial 
size and plays a major role in aorta and other big arteries, while endothelium-dependent 
hyperpolarization plays a major role in smaller resistance arteries (49). Therefore, the 
observed increase in systolic blood pressure in KO mice could be ascribed to NO synthase 
inhibition having a greater effect in the large conduit arteries, than in resistance arteries (45). 
Furthermore, L-NAME administration in the drinking water led to a reduction in heart rate of 
KO animals which was comparable to that observed in WT animals. These results suggest the 
existence of an intact baroreflex response to the increase in peripheral resistance, or at least 
that the response of the cardiovascular system to systemic NO synthesis inhibition is not 
dependent on the VSMC-CaSR.  
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Collectively, the observations described herein support the hypothesis that the loss of the 
CaSR from VSMC leads to a reduction of vascular tone, manifesting in vivo as a reduction in 
diastolic blood pressure, which is dependent on the physical activity of the mice. The 
presence of both a cardiac as well as vascular phenotype in these animals suggests that the 
observed hypotensive phenotype is likely to be accounted for by a combination of CaSR 
ablation from both cardiac and vascular systems and further studies are required to dissect 
these effects in greater detail using cell-specific gene ablation studies in which Cre 
recombinase is driven by alternative promoters. 
It has long been established that the CaSR can translate even minute changes in [Ca
2+
]o into 
intracellular responses (6). These changes in extracellular [Ca
2+
]o can also be elicited by 
extrusion of [Ca
2+
]i – indeed, excitation and subsequent extrusion of [Ca
2+
]i into the 
intracellular space has been conclusively demonstrated to activate the CaSR on neighboring 
cells and elicit intracellular responses in a paracrine fashion, acting in a way as a “third 
messenger” (10, 23, 24, 29). On the basis of our observations in this study and the 
aforementioned considerations, we therefore propose a hypothesis of how the VSMC-CaSR 
and endothelial-CaSR could directly contribute to the maintenance of blood vessel tone 
(Figure 8). A contractile stimulus, e.g. via depolarization or α1-adrenoceptor agonists, leads 
to an increase in Ca
2+
i concentration in VSMC. Restoration of normal resting Ca
2+
i levels is 
achieved in part via extrusion of Ca
2+
i into the interstitium, where it is feasible that such 
localized increase in Ca
2+
o would activate the VSMC-CaSR in an auto-/paracrine fashion, thus 
causing potentiation of contraction. Loss of such a mechanism in the 
SM22α
CaSR
∆flox/∆flox
 mice 
could account for the observed reduction in VSMC contractility, thus leading to the observed 
in vivo hypotension. This role of the CaSR as modulator of VSMC contractility is further 
supported by the fact that, conversely, increased expression of the CaSR and an associated 
increase in [Ca
2+
]i have been reported in pulmonary arterial smooth muscle cells from patients 
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with pulmonary arterial hypertension and surrogate animal models (55) which is alleviated by  
pharmacological CaSR inhibition (20),  
 
Cardiac phenotype 
CaSR ablation from SM22α-positive tissues also leads to its deletion from the developing 
heart (30), which could account for the aforementioned bradycardia in KO mice. Therefore, 
direct loss of the CaSR from the heart could impact negatively on pacemaker frequency or 
intracellular coupling. Previously it has been demonstrated in ventricular cardiomyocytes that 
CaSR activation leads to increased Ca
2+
i signaling and increased cell shortening culminating 
in a positive inotropic effect and modification of their electromechanical coupling (48). 
Isolated ex vivo hearts recapitulated the reduction in heart rate observed by radiotelemetry in 
vivo. Indeed, isolated PVC from KO mice, which show similar electrophysiological hallmarks 
of cardiac pacemaker cells (12, 14, 26, 57), also exhibited reduced lower spontaneous activity 
than cells isolated from WT miceresults suggesting that the observed bradycardia in KO mice 
could be ascribed to decreased pacemaker activity. The observed cardiac remodelling, i.e. 
stronger mode of contraction, together with the increase in dp/dt, could thus be interpreted as 
compensatory response to the bradycardic and hypotensive phenotype. The reduction in 
fibrosis suggests that KO animals might be protected against the development of age-related 
cardiac fibrosis (2), maybe via a beneficial effect of their reduced heart rate (8) but could also 
be a direct consequence of CaSR deletion from the heart, as recently indicated in a rat model 
of cardiac hypertrophy (32). Further studies will be necessary to completely elucidate the role 
of the cardiac CaSR. 
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Conclusions 
Taken together, our studies highlight a physiological role for the CaSR in the cardiovascular 
system. In VSMC, CaSR-mediated regulation of contraction contributes to vessel 
contractility. Loss of this mechanism, likely together with direct cardiac effects, could account 
for the observed hypotension in 
SM22Α
CaSR
∆flox/∆flox
 mice. The net balance between the effects 
of the CaSR in smooth muscle (pro-contractile) and the endothelium (pro-relaxing) 
determines the influence of the vascular CaSR on vascular tone regulation. Furthermore, KO 
mice exhibit both in vivo and ex vivo bradycardia, linking the CaSR to direct modulation of 
cardiac function. The results of our present study thus implicate the CaSR directly in the local 
regulation of the cardiovascular system. 
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Table and figure legends 
Table 1. EC50 values from wire myography experiments detailed in figures 2 and 3 (see there 
for experimental conditions) which were fitted with sigmoidal concentration-response curves, 
with exception of [Ca
2+
]o CRC for WT aortas that could not be fitted with the sigmoidal 
concentration-response curve. Values presented as log(EC50) in mol / L ± SEM. * p < 0.05, 
extra sum-of-squares F-test. 
 
Table 2. Physiological parameters from longitudinal radiotelemetry recordings (c.f. Figures 4 
and 5) from WT and KO mice kept on control drinking water vs. drinking water supplemented 
with L-NAME (0.5 g / L) and on control diet vs. a high salt diet (4 % NaCl-supplemented). 
Mean ± SEM, N = 5, * / + / # p < 0.05, ** / ++ / ## p < 0.01, *** / +++ / ### p < 0.001, two-
way ANOVA with Holm-Sidak post-test, * WT vs. KO (post-test); + WT vs. KO (ANOVA); 
# control vs. L-NAME / high salt (ANOVA). 
 
Figure 1. Characterization of the 
SM22α
CaSR
∆flox/∆flox
 mouse. (A) Typical genotyping of WT 
and KO mice. (B) Representative histological sections of aortae from WT and KO animals 
(N=4), scale bars = 100 µm. (C) Western blot analysis of CaSR expression with Ponceau 
staining as loading control (top and middle panel) and α-smooth muscle actin (α-SM actin; 
bottom panel) expression in endothelium denuded and adventitia-removed, pooled aortae N = 
18 (WT), 17 (KO) mice (D) Relative mRNA expression of the full-length CaSR (exon 6-7 vs. 
WT) in endothelium-denuded, adventitia-removed aortae of WT and KO animals, mean (line) 
± 1SD (box), N = 4, ** p < 0.01, Student’s t-test (performed on ΔΔCt values vs. WT). (E) 
Ca
2+
i concentration ([Ca
2+
]i) in freshly isolated WT and KO VSMC exposed to increasing 
[Ca
2+
]o (0.1-5 mmol / L), reported as fold-changes from baseline values. Curves were fitted as 
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hyperbolic. Mean ± SEM, N = 3 (WT), 4-5 (KO), ** p < 0.01, *** p < 0.001, two-way 
ANOVA with Holm-Sidak post-test and, +++ p < 0.001, extra sum-of-squares F-test for 
curve comparison. 
 
Figure 2. Blood vessel contractility of 
SM22α
CaSR
∆flox/∆flox
 mice is impaired. Aorta (WT, 
N=33; KO, N=30) and mesenteric artery (MA) responses to (A, B) high K
+
 (KCl, 40 mmol / 
L; WT, N=33; KO, N=34), (C, D) phenylephrine (PE, 1 nmol / L – 30 µmol / L), (E, F) 
acetylcholine (ACh, 1 nmol / L – 30 µmol / L, PE-preconstricted to ~ 60% max) and (G, H) 
Ca
2+
o (1-5 mmol / L, PE-preconstricted to ~ 60% max). Results were normalized to the 
averaged maximum control response in WT. Curves were fitted as sigmoidal concentration-
response (for PE and ACh) or third-order polynomial (for Ca
2+
). Mean ± SEM, * p < 0.05, ** 
p < 0.01, *** p < 0.001, Student’s t-test, or two-way ANOVA with Holm-Sidak post-test, 
and ++ p < 0.01, +++ p < 0.001, extra sum-of-squares F-test for curve comparison. 
 
Figure 4. Role of NO in endothelium-dependent relaxation in WT and KO blood vessels. 
Aorta and mesenteric artery (MA) responses to phenylephrine (PE, 1 nmol / L – 30 µmol / L) 
(A, B) in the presence of the NOS inhibitor L-NAME (100 µmol / L) or (C, D) endothelium 
denuded (-E). (E, F) Aorta and MA responses to ACh (1 nmol / L - 30 µmol / L) in the 
presence of L-NAME (100 µmol / L). (G, H) Relaxation of endothelium-denuded (-E) aortae 
and MA from WT and KO mice to increasing concentrations of the NO donor, SNAP. Curves 
were fitted as sigmoidal concentration-response. Mean ± SEM, * p < 0.05, ** p < 0.01, *** p 
< 0.001, two-way ANOVA with Holm-Sidak post-test, and +++ p < 0.001, extra sum-of-
squares F-test for curve comparison. 
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Figure 3. Pharmacological activation of the CaSR in WT and KO blood vessels. Responses to 
NPS R-568 (10 nmol / L – 10 µmol / L) in intact (A) or endothelium denuded (B) aortae. 
Curves were fitted as sigmoidal concentration-response. Mean ± SEM, +++ p < 0.001, two-
way ANOVA. 
 
Figure 5. Tail cuff and radiotelemetry blood pressure measurements of WT and KO animals. 
(A-C): tail cuff measurements of (A) systolic, (B) diastolic and (C) mean arterial pressures 
(MAP) of WT and KO mice. Mean ± SEM, N = 20 (WT), 35 (KO), * p < 0.05, Student’s t-
test. (D-G): Longitudinal radiotelemetry measurements of (D) systolic and (E) diastolic blood 
pressure, (F) MAP and (G) pulse height (PH) of WT and KO mice in the presence or absence 
of L-NAME treatment. Mean ± SEM, N = 5 (WT and KO). 
 
Figure 6. Longitudinal radiotelemetry measurements of (A) heart rate and (B) the positive 
first derivative of the blood pressure curve (dp/dt) of WT and KO mice in the presence or 
absence of L-NAME treatment. Mean ± SEM, N = 5 (WT and KO). 
 
Figure 7. Cardiac phenotype of WT and KO animals. (A) Haematoxylin and eosin staining 
and (B) Picrosirius red staining (right panels) of heart sections showing reduced occurrence of 
fibrosis in KO hearts compared to WT. (C) Representative long-axis MRI scans and (D) 3D 
reconstructions of left ventricles of WT and remodeled KO mice (5 out of 11 investigated) in 
end-diastole and end-systole (lower panels). (E) Left ventricular mass (LVM), (F) left 
ventricular end diastolic (EDV), (G) end systolic (ESV), (H) and stroke volume (SV), (I) 
ejection fraction (EF), (J) diastolic remodeling index (DRI) and (K) wall-thickening (end 
systolic minus end diastolic wall thickness) of remodeled hearts. N = 5, ** p < 0.01, * p < 
0.05, mean ± SEM, Student’s t-test. (L) Base intrinsic heart rate (beats per min, bpm) of ex 
35 
 
vivo retrograde perfused hearts. N = 9 (WT), 10 (KO), * p < 0.05, mean ± SEM, Student’s t-
test.  
 
Figure 8. Hypothetical mechanism for the CaSR mediated auto-/paracrine amplification of 
contraction in vascular smooth muscle cells (VSMC). In VSMC, adrenoceptor (AR) agonists 
(e.g. PE) increase Ca
2+
i concentration, causing blood vessel constriction. Ca
2+
i is then 
extruded from the cell into the interstitium. Locally accumulating Ca
2+
o activates the CaSR on 
the same and neighboring VSMC, thus amplifying and synchronizing VSMC contractility. 
Ca
2+
i is also extruded into the myo-endothelial space (MES) where it can activate the CaSR 
on endothelial cell (EC) projections (EP), which penetrate the internal elastic lamina (EL). 
Activation of the endothelial CaSR leads to VSMC relaxation via a mechanism likely 
involving NO synthesis and endothelium-derived hyperpolarizations (EDH), in a fashion 
similar to dilating agents like acetylcholine (ACh) acting on muscarinic receptors (MR). 
 
36 
 
Legends for supplemental videos 
Video S1 
Characterization of the cardiac phenotype of 
SM22α
CaSR
∆flox/∆flox
 mice. Cardiac cine MRI 
sequence of one heartbeat from three representative WT and three remodeled (5 out of 11 
investigated hearts) KO hearts shown in long axis. 
 
Video S2 
Characterization of the cardiac phenotype of 
SM22α
CaSR
∆flox/∆flox
 mice. Representative video of 
one heartbeat of a WT mouse heart shown as 3D-reconstruction of the left ventricular 
endocardium (red) intersected with short and long axis image planes (black and white) from 
cardiac cine MRI.  
 
Video S3 
Characterization of the cardiac phenotype of 
SM22α
CaSR
∆flox/∆flox
 mice. The left ventricle of 
remodeled hearts from KO mice exhibits full apical closure. Representative video of one 
heartbeat of a remodeled (5 out of 11 investigated hearts) KO mouse heart shown as 3D-
reconstruction of the left ventricular endocardium (red) intersected with short and long axis 
image planes (black and white) from cardiac cine MRI. 
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Tables 
Table 1 
 
Aorta log(EC50) ± SEM (mol / L)  
 
Genotype  
Treatment WT  KO  
PE -6,871 ± 0,083 (N=19) -6,534 ± 0,093 (N=18) * 
PE + L-NAME -7,450 ± 0,106 (N=6) -7,281 ± 0,145 (N=6) ns 
PE - E -7,491 ± 0,164 (N=9) -7,353 ± 0,303 (N=8) ns 
ACh -7,469 ± 0,095 (N=14) -7,475 ± 0,067 (N=15) ns 
ACh + L-NAME -6,150 ± 0,142 (N=4) -6,146 ± 0,263 (N=5) ns 
SNAP -6,892 ± 0,167 (N=5) -6,886 ± 0,279 (N=5) ns 
Calcium NA -2,636 ± 0,081 (N=9)  
   
 
MA log(EC50) ± SEM (mol / L)  
 
Genotype  
Treatment WT KO  
PE -5,875 ± 0,080 (N=16) -5,702 ± 0,070 (N=16) * 
PE + L-NAME -6,047 ± 0,070 (N=11) -5,928 ± 0,095 (N=9) ns 
PE - E -6,352 ± 0,111 (N=10) -6,263 ± 0,120 (N=11) ns 
ACh -7.073  ± 0.056 (N=15)  -6.898 ± 0.072 (N=15)  ns 
ACh + L-NAME -6,374 ± 0,161 (N=9) -6,148 ± 0,182 (N=7) ns 
SNAP -6,717 ± 0,134 (N=6) -6,646 ± 0,071 (N=6) ns 
Calcium -2.832 ± 0,045 (N=10) -2.782 ± 0,046 (N=9) ns 
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Table 2 
 
Night-time  WT Control KO    WT L-NAME KO     
Systolic (mm Hg) 127.3 ± 4.9 112.1 ± 2.6 * 138.7 ± 5.8 126.7 ± 3.1 
 
++ ## 
Diastolic (mm Hg) 101.4 ± 4.9 81.3 ± 2.2 ** 106.7 ± 4.4 88.9 ± 3.9 ** +++ 
 
MAP (mm Hg) 114.6 ± 4.7 97.3 ± 2.4 * 121.8 ± 4.4 107.1 ± 3.4 * +++ # 
PH (mm Hg) 25.8 ± 2.5 30.8 ± 1.5 
 
32.0 ± 3.4 37.8 ± 1.9 
 
+ # 
HR (bpm) 621.1 ± 19.7 515.7 ± 16.1 ** 489.3 ± 29.6 409.1 ± 11.4 * +++ ### 
dp/dt (mm Hg / s) 1934.9 ± 162.3 2437.2 ± 244.3 
 
1884.5 ± 186.8 2436.9 ± 236.2 
 
+ 
 
Day-time  WT Control KO    WT L-NAME KO     
Systolic (mm Hg) 108.6 ± 2.3 106.6 ± 2.3  123.9 ± 3.7 118.9 ± 2.5   ### 
Diastolic (mm Hg) 82.7 ± 1.5 76.8 ± 3.4  95.1 ± 5.6 80.3 ± 3.6 * +  
MAP (mm Hg) 96.0 ± 1.60 92.01 ± 2.8  109.1 ± 4.1 98.9 ± 3.0  + ## 
PH (mm Hg) 26.0 ± 2.0 29.9 ± 1.9  28.8 ± 4.4 38.6 ± 3.0  +  
HR (bpm) 482.8 ± 23.9 459.7 ± 20.0  450.4 ± 23.5 372.2 ± 23.5  + # 
dp/dt (mm Hg / s) 2008.4 ± 95.1 2399.2 ± 259.7  1919.6 ± 279.8 2647.9 ± 261.3  +  
                 
Night-time  WT Control KO    WT High salt KO     
Systolic (mm Hg) 133.5 ± 1.8 126.6 ± 4.4 
 
133.1 ± 4.5 123.5 ± 3.3 
 
+ 
 
Diastolic (mm Hg) 104.1 ± 1.6 92.4 ± 3.8 ** 103.8 ± 1.0 90.5 ± 3.3 ** +++ 
 
MAP (mm Hg) 119.0 ± 1.3 109.7 ± 4.2 * 118.1 ± 2.1 107.1 ± 3.2 * ++ 
 
PH (mm Hg) 29.4 ± 2.0 34.2 ± 1.6 
 
29.3 ± 3.9 33.0 ± 1.1 
   
HR (bpm) 638.9 ± 2.3 545.3 ± 22.8 ** 610.5 ± 19.8 515.2 ± 24.6 ** +++ 
 
dp/dt (mm Hg / s) 2412.1 ± 109.4 2628.5 ± 300.3 
 
2041.8 ± 104.6 2307.4 ± 231.4 
   
Day-time  WT Control KO    WT High salt KO     
Systolic (mm Hg) 116.04 ± 3.2 119.4 ± 3.9  114.0 ± 2.6 113.6 ± 1.9    
Diastolic (mm Hg) 87.15 ± 1.6 84.7 ± 4.1  85.6 ± 1.4 78.6 ± 2.3    
MAP (mm Hg) 101.65 ± 2.4 102.0 ± 4.1  99.7 ± 1.5 95.9 ± 1.9    
PH (mm Hg) 28.88 ± 1.8 34.7 ± 2.3  28.5 ± 2.5 35.0 ± 1.9  +  
HR (bpm) 489.0 ± 13.6 457.7 ± 32.8  469.8 ± 14.0 382.9 ± 9.1 * ++ # 
dp/dt (mm Hg / s) 2181.7 ± 96.1 2451.4 ± 245.8  2197.5 ± 127.3 2293.6 ± 186.3    
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